Ulcerative colitis (UC) is one of the most severe chronic diseases, causing relentless gastrointestinal pain and ...

Ulcerative colitis (UC) is one of the two major types of chronic inflammatory bowel diseases (IBD), along with Crohn’s disease. UC affects the large bowel, has no known cure, and requires lifelong ...

Several medications now calm painful inflammation in the intestines. Diets free of ultraprocessed foods also help ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis. Since ...

Based on the currently available funds and the expected reimbursement of the research tax credits (CIR) from 2024 in the second half of 2025 amounting to EUR 5.7M, Abivax expects to be able to finance ...

EQS-News: ABIVAX / Key word (s): Annual Results Abivax Announces Full Year 2024 Financial Results 24.03.2025 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement.

Probiotics are live microorganisms that may offer certain health benefits, including possible relief of acid reflux symptoms.

The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

J&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease ...